fouremm - Thank you for pointing to that chart. Since that presentation DM has suggested the payers might now be willing to pay up to $5,000 per year versus $4,200 per year and the chart does not take into account any Alzheimer's revenue or the most recent potential, the 36.7 million strong HIV market if that ever gets any legs. The chart you refer to suggests 64% market penetration, Dr Kedeckle's valuation of $8.55 per share is based on just 2% market penetration. Needless to say there is a vast amount of space for wiggle room.

dyodd

tada